Table of Contents
Chapter 1 Report Scope and Objectives
1.1 Market Segmentation & Scope
1.2 Regional Scope
1.2.1 Estimates And Forecast Timeline
1.3 Objectives
1.3.1 Objective – 1
1.3.2 Objective – 2
1.3.3 Objective – 3
Chapter 2 Methodology
2.1 Research Methodology
2.2 Information Procurement
2.2.1 Purchased Database
2.2.2 Gvr’s Internal Database
2.2.3 Secondary Sources
2.2.4 Primary Research
2.3 Information Or Data Analysis
2.3.1 Data Analysis Models
2.4 Market Formulation & Validation
2.5 Model Details
2.5.1 Commodity Flow Analysis (Model 1)
2.5.2 Volume Price Analysis (Model 2)
2.6 List Of Secondary Sources
Chapter 3 Executive Summary
3.1 Market Outlook
3.2 Segment Outlook
3.2.1 Application
3.2.4 Region
3.3 Competitive Insights
3.4 Healthcare Bioconvergence Market Outlook, 2021
Chapter 4 Market Variables, Trends & Scope
4.1 Market Lineage Outlook
4.1.1 Parent Market Outlook
4.2 Healthcare Bioconvergence Market Dynamics
4.2.1 Market Driver Analysis
4.2.2 Market Restraint Analysis
4.3 Healthcare Bioconvergence: Business Environment Analysis Tools
4.3.1 Porter’s Five Forces Analysis
4.3.1.1 Competitive Rivalry
4.3.1.2 Threat Of Substitutes
4.3.1.3 Threat Of Entrants
4.3.1.4 Bargaining Power Of Buyers
4.3.1.5 Bargaining Power Of Suppliers
4.3.2 Pestel Analysis
4.3.2.1 Political & legal
4.3.2.2 Economic & social
4.3.2.3 Technological
4.4 Penetration & Growth Prospect Mapping
4.5 Impact of COVID-19 on Healthcare Bioconvergence Market
Chapter 5 Healthcare Bioconvergence Market: Application Analysis
5.1 Healthcare Bioconvergence Application Market Share Analysis, 2021 & 2030
5.2 Healthcare Bioconvergence Application Market: Segment Dashboard
5.3 Market Size & Forecasts and Trend Analyses, 2017 to 2030 for the Application Segment
5.3.1 Drug Discovery
5.3.1.1 Drug Discovery Market, 2017 – 2030 (USD Million)
5.3.2 Nanorobotics For Drug Delivery
5.3.2.1 Nanorobotics For Drug Delivery Market, 2017 – 2030 (USD Million)
5.3.3 Regenerative Medicine
5.3.3.1 Regenerative Medicine Market, 2017 – 2030 (USD Million)
5.3.4 Diagnostic And Biological Sensors
5.3.4.1 Diagnostic And Biological Sensors Market, 2017 – 2030 (USD Million)
5.3.5 Bioelectronics
5.3.5.1 Bioelectronics Market, 2017 – 2030 (USD Million)
5.3.6 Engineered Living Materials
5.3.6.1 Engineered Living Materials Market, 2017 – 2030 (USD Million)
5.3.7 Optogenetics
5.3.7.1 Optogenetics Market, 2017 – 2030 (USD Million)
5.3.8 Precision Medicine
5.3.8.1 Precision medicine market, 2017 – 2030 (USD Million)
Chapter 6 Healthcare Bioconvergence Market: Regional Analysis
6.1 Healthcare Bioconvergence Regional Market Share Analysis, 2021 & 2030
6.2 Regional Market Snapshot
6.3 North America
6.3.1 North America Healthcare Bioconvergence Market, 2017 – 2030 (USD Million)
6.3.2 U.S.
6.3.2.1 U.S. Healthcare Bioconvergence Market, 2017 – 2030 (USD Million)
6.3.3 Canada
6.3.3.1 Canada Healthcare Bioconvergence Market, 2017 – 2030 (USD Million)
6.4 Europe
6.4.1 Europe Healthcare Bioconvergence Market, 2017 – 2030 (USD Million)
6.4.2 U.K.
6.4.2.1 U.K. Healthcare Bioconvergence Market, 2017 – 2030 (USD Million)
6.4.3 Germany
6.4.3.1 Germany Healthcare Bioconvergence Market, 2017 – 2030 (USD Million)
6.4.4 France
6.4.4.1 France Healthcare Bioconvergence Market, 2017 – 2030 (USD Million)
6.4.5 Italy
6.4.5.1 Italy Healthcare Bioconvergence Market, 2017 – 2030 (USD Million)
6.4.6 Spain
6.4.6.1 Spain Healthcare Bioconvergence Market, 2017 – 2030 (USD Million)
6.4.7 Russia
6.4.7.1 Russia Healthcare Bioconvergence Market, 2017 – 2030 (USD Million)
6.5 Asia Pacific
6.5.1 Asia Pacific Healthcare Bioconvergence Market, 2017 – 2030 (USD Million)
6.5.2 Japan
6.5.2.1 Japan Healthcare Bioconvergence Market, 2017 – 2030 (USD Million)
6.5.3 China
6.5.3.1 China Healthcare Bioconvergence Market, 2017 – 2030 (USD Million)
6.5.4 India
6.5.4.1 India Healthcare Bioconvergence Market, 2017 – 2030 (USD Million)
6.5.5 Australia
6.5.5.1 Australia Healthcare Bioconvergence Market, 2017 – 2030 (USD Million)
6.5.6 South Korea
6.5.6.1 South Korea Healthcare Bioconvergence Market, 2017 – 2030 (USD Million)
6.5.7 Singapore
6.5.7.1 Singapore Healthcare Bioconvergence Market, 2017 – 2030 (USD Million)
6.6 Latin America
6.6.1 Latin America Healthcare Bioconvergence Market, 2017 – 2030 (USD Million)
6.6.2 Brazil
6.6.2.1 Brazil Healthcare Bioconvergence Market, 2017 – 2030 (USD Million)
6.6.3 Mexico
6.6.3.1 Mexico Healthcare Bioconvergence Market, 2017 – 2030 (USD Million)
6.6.4 Argentina
6.6.4.1 Argentina Healthcare Bioconvergence Market, 2017 – 2030 (USD Million)
6.6.5 Colombia
6.6.5.1 Colombia Healthcare Bioconvergence Market, 2017 – 2030 (USD Million)
6.7 Middle East And Africa (Mea)
6.7.1 Mea Healthcare Bioconvergence Market, 2017 – 2030 (USD Million)
6.7.2 South Africa
6.7.2.1 South Africa Healthcare Bioconvergence Market, 2017 – 2030 (USD Million)
6.7.3 Saudi Arabia
6.7.3.1 Saudi Arabia Healthcare Bioconvergence Market, 2017 – 2030 (USD Million)
6.7.4 Uae
6.7.4.1 Uae Healthcare Bioconvergence Market, 2017 – 2030 (USD Million)
6.7.5 Israel
6.7.5.1 Israel healthcare bioconvergence market, 2017 – 2030 (USD Million)
Chapter 7 Competitive Analysis
7.1 Recent Developments & Impact Analysis, By Key Market Participants
7.2 Company Profiles
7.2.1 BIOMX.
7.2.1.1 Company overview
7.2.1.2 Financial performance
7.2.1.2 Product benchmarking
7.2.1.3 Strategic initiatives
7.2.2 SINGOTA SOLUTION
7.2.2.1 Company overview
7.2.2.2 Product benchmarking
7.2.3 ANIMA BIOTECH INC.
7.2.3.1 Company overview
7.2.3.3 Product benchmarking
7.2.4 GINKGO BIOWORKS
7.2.4.1 Company overview
7.2.4.2 Product benchmarking
7.2.4.3 Strategic initiatives
7.2.5 SETPOINT MEDICAL CORPORATION
7.2.5.1 Company overview
7.2.5.2 Product benchmarking
7.2.5.3 Strategic initiatives
7.2.6 ZYMERGEN INC.
7.2.6.1 Company overview
7.2.6.2 Product benchmarking
7.2.6.3 Strategic initiatives
7.2.7 GALVANI BIOELECTRONICS
7.2.7.1 Company overview
7.2.7.2 Product benchmarking
7.2.8 BICO – THE BIO CONVERGENCE COMPANY
7.2.8.1 Company overview
7.2.8.2 Financial performance
7.2.8.3 Product benchmarking
7.2.8.4 Strategic initiatives
Chapter 8 KOL Commentary
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/